American Association of Critical Care Nurses Adds Its Voice to Intraosseous Access Support Through Endorsement of Infusion Nursing Society`s Position Paper

SAN ANTONIO--(Business Wire)--
The American Association of Critical Care Nurses (AACN), a national organization
of professionals that represents more than 500,000 nurses who care for acute and
critically ill patients, has announced its endorsement of the Infusion Nurses
Society`s (INS) official position on intraosseous (IO) vascular access. The AACN
consistently seeks to ensure the highest safety for patient care as well as best
practices and supports the INS conclusion that use of IO by properly trained
registered nurses, "has now expanded into the non-emergent setting when
intravenous access cannot be obtained and when the patient might be at risk of
increased morbidity or even mortality if access is not obtained." (The entire
INS position paper can be found at
http://www.ins1.org/i4a/pages/index.cfm?pageid=3412.)

This endorsement by AACN illustrates the continuing rapid acceptance of
Intraosseous Access in the medical field in all situations in which immediate
vascular access is medically necessary, and it identifies IO access as an
alternative in patients when traditional vascular access cannot be obtained.

Phil Faris, President and CEO of Vidacare Corporation, the developer and
manufacturer of the EZ-IO® Vascular Access System, which has become the
technology standard for IO vascular access in both pediatric and adult patients,
commented, "We are pleased that this prestigious organization has endorsed the
position that intraosseous access is an important method of vascular access for
the field of critical care nursing.The role of critical care nurses in
establishing IO access when needed can be one that is truly life saving, and we
look forward to building a strong foundation of education and awareness with
this group of medical professionals."

Intraosseous infusion is a technique for accessing the central circulation
through blood vessels within the bone marrow that are held open by a rigid,
non-collapsible bony wall. Drugs and medications delivered via this route reach
the central circulation within seconds. The use of IO has been associated with
few complications.*

Established in 2001, Vidacare Corporation is the developer of a broad technology
platform that is defining the new field of intraosseous (inside the bone)
medicine, with the potential to establish new standards of clinical excellence
in the safe, rapid performance of medical procedures using the intraosseous
space. Current applications include vascular access, emergency and disaster
medicine, oncology, spinal surgery applications and regenerative medicine.
Vidacare`s focus on enhancing clinical efficacy, patient safety and comfort, and
reducing complications and their associated costs, has resulted in its devices
becoming the recognized technology standard in their respective clinical fields.
Privately held, the company is based in San Antonio, Texas and its products are
marketed in over 50 countries worldwide.

*There are several contraindications to intraosseous placement. These include
fracture; a recent orthopedic procedure or prosthetic limb; intraosseous
placement in a limb within 24 hours; infection over the site and the inability
to correctly identify landmarks.

for Vidacare
Lisa Owens, 210-601-6647
lisaowens@regval.com

Copyright Business Wire 2010